Guinn D A, Atkinson M W, Sullivan L, Lee M, MacGregor S, Parilla B V, Davies J, Hanlon-Lundberg K, Simpson L, Stone J, Wing D, Ogasawara K, Muraskas J
Maternal Fetal Medicine, Denver Health Medical Center, 777 Bannock St, MC 0660, Denver, CO 80204, USA.
JAMA. 2001 Oct 3;286(13):1581-7. doi: 10.1001/jama.286.13.1581.
The practice of administering weekly courses of antenatal corticosteroids to pregnant women at risk of preterm delivery is widespread, but no randomized trial has established the efficacy or safety of this practice.
To evaluate the efficacy of weekly administration of antenatal corticosteroids compared with a single course in reducing the incidence of neonatal morbidity and to evaluate potential complications of weekly treatment.
Randomized, double-blind, placebo-controlled intention-to-treat trial conducted in 13 academic centers in the United States from February 1996 through April 2000.
A total of 502 pregnant women between 24 and 32 completed weeks' gestation who were at high risk of preterm delivery.
All patients received a complete single course of antenatal corticosteroids (either betamethasone, 12 mg intramuscularly repeated once in 24 hours for 2 doses, or dexamethasone, 6 mg intramuscularly repeated every 12 hours for 4 doses). Participants who had not delivered 1 week after receipt of the single course were randomly assigned to receive either betamethasone, 12 mg intramuscularly repeated once in 24 hours for 2 doses every week until 34 weeks' gestation or delivery, whichever came first (n = 256), or a similarly administered placebo (n = 246).
Composite neonatal morbidity (including severe respiratory distress syndrome, bronchopulmonary dysplasia, severe intraventricular hemorrhage, periventricular leukomalacia, proven sepsis, necrotizing enterocolitis, or perinatal death).
Composite morbidity occurred in 22.5% of the weekly-course group vs 28.0% of the single-course group (unadjusted relative risk, 0.80; 95% confidence interval, 0.59-1.10). Neither group assignment nor the number of treatment courses was associated with a reduction in composite morbidity.
Weekly courses of antenatal corticosteroids did not reduce composite neonatal morbidity compared with a single course of treatment. Weekly courses of antenatal corticosteroids should not be routinely prescribed for women at risk of preterm delivery.
对有早产风险的孕妇每周使用产前皮质类固醇进行治疗的做法很普遍,但尚无随机试验证实这种做法的有效性或安全性。
评估每周使用产前皮质类固醇与单次使用相比在降低新生儿发病率方面的有效性,并评估每周治疗的潜在并发症。
1996年2月至2000年4月在美国13个学术中心进行的随机、双盲、安慰剂对照的意向性治疗试验。
共有502名妊娠24至32周、有早产高风险的孕妇。
所有患者均接受完整的单次产前皮质类固醇治疗(倍他米松,12毫克肌肉注射,24小时后重复一次,共2剂;或地塞米松,6毫克肌肉注射,每12小时重复一次,共4剂)。接受单次治疗1周后未分娩的参与者被随机分配接受倍他米松治疗,12毫克肌肉注射,24小时后重复一次,每周2剂,直至妊娠34周或分娩,以先到者为准(n = 256),或接受同样给药的安慰剂(n = 246)。
复合新生儿发病率(包括严重呼吸窘迫综合征、支气管肺发育不良、严重脑室内出血、脑室周围白质软化、确诊败血症、坏死性小肠结肠炎或围产期死亡)。
每周治疗组的复合发病率为22.5%,单次治疗组为28.0%(未调整相对风险,0.80;95%置信区间,0.59 - 1.10)。分组和治疗疗程数均与复合发病率的降低无关。
与单次治疗相比,每周使用产前皮质类固醇并未降低复合新生儿发病率。对于有早产风险的女性,不应常规开具每周使用产前皮质类固醇的处方。